Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study
Paul B. Chapman(Memorial Sloan Kettering Cancer Center), Grant A. McArthur(The University of Melbourne), Keith T. Flaherty(Cancer Research Center), Omid Hamid(Cedars-Sinai Medical Center), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Axel Hauschild(University Hospital Schleswig-Holstein), Ilsung Chang, Samuel S. Coleman, David Hogg(University of Leeds), Paul Lorigan(Manchester Academic Health Science Centre), Ivor Caro(Genentech), Jeffrey A. Sosman(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), James Larkin(Trinity College Dublin), Antoni Ribas(University of California, Los Angeles), Reinhard Dummer(University Hospital of Zurich), John B.A.G. Haanen(Leiden University Medical Center), Caroline Robert(Institut Gustave Roussy), Alessandro Testori(European Organisation for Research and Treatment of Cancer)
Cited by 258
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k